Cervical Cancer by FIGO Stage 2018
Conditions
Brief summary
This is a single-arm, prospective, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for locally advanced cervical cancer will translate into a decreased rate of acute gastrointestinal toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT). The timepoint for this assessment will be at week 5 of external beam radiotherapy (EBRT) and will use the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Interventions
Daily adaptive external beam radiation therapy delivered on Varian Ethos treatment system.
Sponsors
Varian, a Siemens Healthineers Company
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients must have histologically confirmed, newly diagnosed advanced cervical cancer (squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma): FIGO 2018 clinical stages IB2-IVA, without involved paraaortic lymph nodes. 2. For patients with involved pelvic lymph nodes, the upper border of the CTV nodal volume may not extend above the confluence of the common iliac arteries with the aorta (i.e., aortic bifurcation). 3. Patients must NOT have had a hysterectomy. 4. Pelvic nodal status is to be confirmed by one or more of the following studies/procedures: PET/CT scan, CT scan, MR Scan, fine needle biopsy, extra peritoneal biopsy or laparoscopic biopsy, per institutional standard of care. 5. Patients must be planning to undergo concurrent pelvic radiation and chemotherapy. 6. ECOG performance status ≤ 2 (Karnofsky ≥60%). 7. Patient must be willing and able to complete the PRO-CTCAE, EQ-5D, EPIC and EORTC questionnaires as described in the study protocol. 8. Patient must have normal organ and marrow function as defined below: * leukocytes ≥ 2,500/mcL * absolute neutrophil count ≥ 1,500/mcL * platelets ≥ 100,000/mcL * hemoglobin ≥ 8 g/dL (can be transfused with red blood cells pre-study) * total bilirubin ≤ 1.5 × institutional upper limit of normal (ULN) * AST(SGOT)/ALT(SGPT) ≤ 3 × ULN * alkaline phosphatase ≤ 2.5 × ULN * creatinine \< 1.5 mg/dL to receive weekly cisplatin\* * Patients whose serum creatinine is between 1.5 and 1.9 mg/dL are eligible for cisplatin if there is no hydronephrosis and the estimated creatinine clearance (CCr) is \>30 ml/min. For the purpose of estimating the CCr, the formula of Cockcroft and Gault for females should be used:CCr=(0.85 ×(140-age)×IBW)/((Scr×72)) where age is the patient's age in years (from 20 to 80 years), Scr is the serum creatinine in mg/dL, and IBW is the ideal body weight in kg (according to the calculation IBW = 45.5 kg + 2.3 kg for each inch over 5 feet). 9. Age ≥ 18 years (or meets local age of consent). 10. Study participant is already intending to be prescribed a standard of care cisplatin treatment regimen. 11. Ability to understand and the willingness to sign a written informed consent document.
Exclusion criteria
1. Prior radiation therapy to the pelvis or abdominal cavity, para-aortic lymph glands (PALN) radiation, or previous therapy of any kind for this malignancy. 2. Patients with PALN nodal metastasis. 3. Patients who have undergone staging pelvic and/or paraaortic lymphadenectomy. 4. Prior allogeneic bone marrow transplantation or prior solid organ transplantation. 5. Prior systemic anticancer therapy due to a diagnosis of cancer (e.g., chemotherapy, targeted therapy, immunotherapy) within 3 years prior to entering the study. 6. Patients diagnosed on imaging or biopsy with a synchronous primary malignancy (with the exception of DCIS of the breast, or early stage basal cell carcinoma of the skin). 7. Patients with a history of inflammatory bowel disease, including ulcerative colitis and Crohn's Disease. 8. Patients with a history of other symptomatic autoimmune disease: rheumatoid arthritis, systemic progressive sclerosis (scleroderma), systemic lupus erythematosus, autoimmune vasculitis (e.g., Wegener's Granulomatosis); CNS or motor neuropathy considered of autoimmune origin (e.g., Guillain-Barre Syndrome and Myasthenia Gravis, multiple sclerosis.). 9. Patients with active tuberculosis (TB). 10. Patients who are pregnant. 11. Patients who are actively breastfeeding (or who do not agree to discontinue breastfeeding before the initiation of protocol therapy). 12. Patients who are of child-bearing potential who do not agree to use birth control (for a minimum of 14 months after the last dose of cisplatin) in accordance with institution's standard of care. 13. Patients with a prior known history or current diagnosis of a vesicovaginal, enterovaginal, or colovaginal fistula. 14. Patients who undergo a pelvic or para-aortic lymph node dissection prior to planned chemoradiation therapy. 15. Patients with known active infection of HIV. 16. Patients with hip prosthetics
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Acute Patient Reported Outcome (PRO) GI Toxicity | End of external beam treatment delivery (week 5) | GI toxicity as reported by the patient using the gastrointestinal section of the NCI-PRO questionnaire |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Acute PRO Bowel Toxicity | End of external beam treatment delivery (week 5) | Bowel toxicity as reported with EPIC bowel questionnaire |
| Acute PRO Urinary Toxicity | End of external beam treatment delivery (week 5) | Urinary toxicity as reported with EPIC urinary questionnaire |
| Patient Reported Quality by EQ-5D-5L | 24 months post treatment | Quality of life as document with EQ-5D-5L patient reported questionnaire |
| Patient Reported Quality by EORTC | 24 months post treatment | Quality of life as document with EORTC patient reported questionnaire |
| Key powered secondary endpoint: Fecal Urgency | End of external beam treatment delivery (week 5) | Acute reported fecal urgency (as measured by the inability to defer defecation by 15 minutes) |
| Normal Tissue Complication Probability Model | Enrollment through 2 year follow up | Develop a normal tissue complication probability (NTCP) model of acute GI toxicity based on true integrated daily dose to the bowel |
| Workflow Feasibility | End of external beam treatment delivery | Record percentage of fractions delivered with adaptive radiation therapy vs traditional IGRT |
| CTCAE Toxicities | Enrollment through 2 year follow up | Physician reported CTCAE toxicities |
| Disease-free Survival | Enrollment through 2 year follow up | Disease-free survival at 2 years |
Countries
United States
Contacts
Primary ContactHeike Hausen, MD
Backup ContactSean Davidson, MS
Outcome results
None listed